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Introduction: Multiple myeloma (MM) is a haematological tumour that is characterised by
uncontrolled proliferation of plasma cells and a signiﬁcant volume of serum free light chains
(sFLCs), which can cause acute renal failure due to intratubular precipitation, resulting in
cast  nephropathy.
Acute renal failure is a complication that can arise in more than 20% of patients with
multiple myeloma, half of which will require dialysis.
Methods: We  report our experience with 13 patients who were treated with dialysis using
high  cut off ﬁlters (HCO) between July 2011 and February 2015.
A  total of 6 consecutive 6-h sessions were performed using a 2.1 m2 HCO ﬁlter (Theralite®
by Gambro®). Afterwards, further 6-h sessions were continued on alternate days.
Results: A total of 151 sessions were conducted, with an average of 11.6 sessions per patient
(range 6–27).
The treatment proved to be effective in removing both kappa and lambda sFLCs, resulting
in  a 93.7% fall in sFLCs by the end of treatment. The average reduction was 57.7% per dialysis
session. 10 out of the 13 cases recovered sufﬁcient renal function to become independent
of  dialysis.or changes in albumin levels using an infusion protocol of 2 50-ml vialsThere were no majof  20% albumin at the end of the dialysis session.
Conclusions: Combination treatment with chemotherapy and long dialysis with HCO ﬁl-
ters  was effective in reducing the sFLC levels and recovering sufﬁcient renal function in
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77% of cases. With HCO ﬁlters, signiﬁcant cost savings are achieved, contrary to what was
previously believed.
©  2016 Sociedad Espan˜ola de Nefrologı´a. Published by Elsevier Espan˜a, S.L.U. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
Trece  tratamientos  de  la  insuﬁciencia  renal  aguda  secundaria  a  mieloma
múltiple  con  ﬁltros  de  high  cut  off
Palabras clave:
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Diálisis con ﬁltros de high cut off
r  e  s  u  m  e  n
Introducción: El mieloma múltiple (MM) es una tumoración hematológica que se caracteriza
por la proliferación incontrolada de células plasmáticas y la existencia de una importante
cantidad de cadenas libres en sangre (CLLs) que puede ocasionar un fallo renal agudo por
la  precipitación intratubular de ellas, causando nefropatía por cilindros.
La  insuﬁciencia renal aguda es una complicación que puede presentarse en más de un 20%
de  los pacientes con MM, y la mitad de estos precisarán diálisis.
Métodos: Presentamos nuestra experiencia de 13 pacientes tratados con diálisis mediante
ﬁltros de high cut off (HCO), durante el período comprendido entre julio de 2011 y febrero de
2015.
Se  realizan 6 sesiones consecutivas de 6 h de duración, utilizando un ﬁltro de HCO
(Theralite® de Gambro®) de 2,1 m2 de superﬁcie. Posteriormente se continúa con sesiones a
días  alternos de igual duración.
Resultados: Se realizaron un total de 151 sesiones; una media de 11,6 sesiones/paciente (rango
6–27).
El  tratamiento se mostró efectivo para eliminar tanto CLLs kappa como lambda. El por-
centaje de disminución de CLLs desde el inicio hasta el ﬁnal del tratamiento fue del 93,7%.
La  reducción media por sesión de diálisis fue del 57,7%. En 10 de los 13 casos se recuperó la
función renal y los pacientes pudieron permanecer sin diálisis.
No  hubo grandes cambios en los niveles de albúmina utilizando un protocolo de infusión
de  2 viales de 50 mL de albúmina al 20% al ﬁnal de la sesión de diálisis.
Conclusiones: El tratamiento combinado con quimioterapia más diálisis largas con ﬁltros
de  HCO resultó eﬁcaz para reducir el nivel de CLLs y recuperar un nivel de función renal
suﬁciente en el 77% de los casos. Con ﬁltros de HCO se consigue un ahorro signiﬁcativo, en
contraposición a lo descrito previamente en la literatura.
©  2016 Sociedad Espan˜ola de Nefrologı´a. Publicado por Elsevier Espan˜a, S.L.U. Este es un
artı´culo Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/licenses/
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mntroduction
ultiple myeloma (MM)  is a neoplastic disease characterised
y uncontrolled proliferation of plasma cells in the bone
arrow.1 This produces an excessive release of immunoglob-
lins and their fragments called light chains, The formation
f cast in the distal tubules as a result of the deposit of light
hains along with the Tamm–Horsfall protein causes renal
ailure in these patients.2,3
There are two types of light chain: kappa, which is a
onomeric form with a molecular weight of 22.5 kDa; and
ambda, which are dimers, with a molecular weight of 45 kDa.
MM accounts for 0.1% of all cancers. In Spain, it represents
3% of all haematological cancers, with over 2000 new cases
very year and an incidence of 5–6 cases/100,000 population.4M is observed in adults; only 15% of cases are under 50, and
he peak incidence is between the ages of 60 and 70. It affects
en  more  than women and black people more  than white.5by-nc-nd/4.0/).
Life expectancy is less than a year if the patient develops
renal failure, although with treatment, it can prolonged to 5–7
years.5,6
Acute renal failure may occurs in up to 20% of MM patients
and half of them may require dialysis. The acute renal failure
may be aggravated by different circumstances, such as dehy-
dration, hypercalcaemia, hyperuricaemia, hyperviscosity,7
and the use of nephrotoxic drugs.
At the beginning of the disease, clinical signs are non-
speciﬁc, an this may delay the diagnosis. The ﬁrst symptoms,
such as bone pain, pathological fractures, anaemia, fatigue,
hypercalcaemia, infections, acute renal failure and others, is
usually presented late.
Acute or chronic kidney disease makes the prognosis much
worse.
The causes of renal dysfunction in patients with myeloma
include alteration to the proximal and distal tubules as a result
of tubular cell damage caused by ﬁltered light chains, cast
nephropathy, amyloidosis, light- or heavy-chain deposition
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disease,8 cryoglobulinaemia, interstitial inﬁltration by plasma
cells and, in rare cases, proliferative glomerulonephritis or
interstitial nephritis.9
There are three main treatment strategies for acute renal
failure:
1. Eliminate factors that aggravate nephrotoxicity and cast
formation; this is achieved with adequate hydration (2–3 l
of ﬂuids per day). Volume depletion will reduce ﬂow
through the tubules and increases the concentration of
free light chains (FLC), and the formation of aggregates.
Avoid furosemide (only if euvolaemic). Avoid nephrotoxic
drugs, especially non-steroidal anti-inﬂammatory drugs,
angiotensin-converting enzyme inhibitors, angiotensin II
receptor antagonists and exposure to contrast agents.
Treat hyperuricaemia. Treat hypercalcaemia (if calcium
is not greater than 14 mg/dl, administer ﬂuids and if
hypercalcaemia persists, add bisphosphonates; if cal-
cium > 14 mg/dl, administer bisphosphonates from the
beginning).
2. Eliminate or reduce the production of FLC by cancer cells.
The usual chemotherapy regimen used in MM improves
renal failure in approximately 50% of cases and tubular
injury responds better than glomerular damage.10
From the point of view of chemotherapy, it should be noted
that the treatment of MM has been markedely changed in
recent years. For years, the standard treatment for these
patients was dexamethasone plus melphalan (alkylating
agent). New drugs have appeared in the last few years that
have resulted in longer survival:
Bortezomib, which has been one of the major advances in
the treatment of MM.
Thalidomide and lenalidomide, already being used for
some years for the treatment of relapsed patients and,
lately, pomalidomide has appeared.11
Bendamustine (alkylating) and melﬂufen, seeking a less
toxic and more  speciﬁc effect than other alkylating
agents.12
Lastly, monoclonal antibodies, which are directed specif-
ically against tumour cell targets. These new molecules
include elotuzumab, CD38 and SLAM-F7; and others which
are still being studied.13,14
All these new alternatives encourage us to be optimistic
about the future of MM and the current idea is that patients
are not completely cured, at least we should be able to turn
MM into a chronic disease.
3. Eliminate or reduce the circulating FLC. Kidney recovery is
associated with an early reduction in serum FLC. Hutchi-
son, using high cut-off (HCO) ﬁlters and long haemodialysis
sessions of 6 h, obtained FLC reductions of over 85%; up to
60% of patients recovered sufﬁcient kidney function to no
longer need dialysis.15
The traditional extracorporeal puriﬁcation methods, such
as haemodialysis or plasmapheresis, do not effectively remove
FLC. In conventional dialysis, the dialysis membrane does not
have the right pore size to remove FLC thus the clearance
is minimal. Plasmapheresis only removes 10–20% of the FLC
(from in the intravascular space), the rest are in the extravas-
cular space, which makes it difﬁcult to remove, added to the;3 6(4):418–426
fact that plasmapheresis causes a signiﬁcant loss of essential
proteins.16,17
Another technique is haemodiaﬁltration with regenera-
tion of the ultraﬁltrate by adsorption in resin (SUPRA-HFR),
which uses convection, adsorption and diffusion with a dual-
chamber dialyser.18,19 Although it is somewhat cheaper but
only few studies have been conducted with very few patients.
Moreover, it only seems to be useful in kappa chains and not
lambda chains.
Another type of membrane has recently been devel-
oped called high-permeability, high-pore or HCO membranes.
These membranes are effective in reducing light chains in
blood (up to 90%) for extended periods of 6–8 h.15 Early diag-
nosis and treatment in reducing FLC in the ﬁrst three weeks
has been shown to be associated with a signiﬁcant increase
in survival.20 The pore size is effective for FLC removal, but it
also leads to protein losses through the dialysis membrane,
which means that albumin has to be administered at the end
of each session. Other supplements are usually required dur-
ing haemodialysis sessions, the most common being calcium,
phosphorus, magnesium and potassium.
Objective
The purpose of this article is to present our experience of 13
cases of treatment of acute renal failure secondary to MM with
HCO ﬁlters.
Methods
We used an Integra Hospal® monitor equipped with 1.4 m2
ultraﬁlters, ultrapure water, bicarbonate cartridge (Bicart®
from Hospal®) and closed-loop central acid-delivery system.
The circuit was primed with Prontoprime® 2000 ml  at a rate
of 100 ml/min and with ultraﬁltration of 2 kg/h; it is important
to prime the blood circuit carefully to avoid the presence of
air bubbles that causes clotting and reduce the efﬁcacy of the
dialysis.
The dialysis membrane used in all cases was a Gambro®
Theralite® 2.1 m2 HCO ﬁlter.
Dialysis was performed daily for a six day period, then,
every other day, until FLC levels in blood fell below 500 mg/l
or kidney function recovered to the point that dialysis could
be discontinued.
The dialysis sessions lasted 6 h with low blood ﬂow rates
(250–300 ml/min) and dialysate ﬂow rate of 500 ml/min. The
dialysate had potassium concentration of 3 mEq/l to avoid
hypokalaemia, especially in the period of daily dialysis Other
components were: calcium 3.5 mEq/l, magnesium 0.9 mEq/l,
sodium 0.139 mEq/l and glucose 1.5 g/l.
The standard heparin regimen was: 2500 IU of sodium hep-
arin at the commencement of dialysis given as a bolus and
followed by the continuous infusion of 1500 IU per hour, stop-
ping 30 min  before the end of the dialysis session.Supplements were administered during the dialysis ses-
sions; the pore size leads to the loss of protein through the
dialysis membrane, so albumin has to be administered at the
end of the session, two vials of 50 ml  of human albumin 20%
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Table 1 – Personal data, kidney biopsy, number of dialysis sessions, symptoms, chain type, treatment, bone marrow
inﬁltration.
Patient Gender Age Kidney
biopsy
No. dialysis
(HCO)
Symptoms FLC type Chemotherapy % BM inﬁltration
1 M 57 GD 27 Progression MGUS Lambda Lena + Dexa 17
2 M 49 ND 7 Lumbar pain Kappa Borte + Dexa 54
3 M 67 ND 9 Lumbar pain Kappa Borte + Dexa 57
4 M 64 ND 7 Asymptomatic Lambda Borte + Dexa 91
5 M 43 GD 13 Sg Kappa Borte + Dexa 93
6 F 69 ND 6 Asymptomatic Lambda Borte + Dexa 71
7 M 61 CN 17 Lumbar pain + diarrhoea Lambda Borte + Dexa 95
8 M 63 CN 10 Sg Kappa Borte + Dexa 13
9 M 71 CN 11 Lumbar pain + Sg Kappa Borte + Dexa 5 Plasmo
10 F 63 CN 12 Sg Lambda Borte + Dexa 44
11 F 70 CN 6 Lumbar pain Lambda Borte + Dexa CN
5 bis M 45 ND 10 Relapse Kappa Borte + Dexa+ Lena Relapse
12 M 53 GD 16 Lumbar pain Kappa Borte + Dexa+ CP 33
Borte: bortezomib; CP: cyclophosphamide; FLC: free light chains; Dexa: dexamethasone; GD: glomerular deposits; HCO: number of dialysis
; CN:
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tsessions with high cut-off ﬁlter; Lena: lenalidomide; BM: bone marrow
syndrome.
20 g). Other supplements, such as calcium gluconate, magne-
ium sulphate and epoetin beta were necessary occasionally.
The usual vascular access was a temporary catheter (Shal-
on) placed in the right jugular vein; catheters were sealed
ith 1% sodium heparin. In one patient, it was necessary
o insert a permanent tunnelled Tesio® catheter. Both tech-
iques were performed by nephrologists from our Nephrology
epartment.
We monitored renal function, free light chains (FLC) in
lood with the Freelite Binding Site® system pre- and post-
ialysis, urea, creatinine, chloride and sodium, and potassium
oth pre- and post-dialysis. In addition, pre-dialysis, total
alcium, ionised calcium, magnesium and blood count were
easured, plus albumin mid-session and, once again post-
ialysis, urea, creatinine and electrolytes. We  also have a
rotocol for determining HBV, HCV and HIV serology at the
tart of dialysis.
Hourly blood ﬂow rates, venous pressure, hourly and total
ltraﬁltration, blood pressure and heart rate, temperature,
edication administration and any incidents occurring dur-
ng the dialysis session were recorded on the nursing chart.21
All patients signed one informed consent form for the
nsertion of vascular access and another for the haemodial-
sis.
esults
ver a period of 43 months, from July 2011 to February 2015, we
erformed 13 treatments using haemodialysis with HCO ﬁlter
n patients with acute renal failure secondary to MM. There
ere in fact only 12 patients, as one had a relapse and was
reated a second time.
There were nine males and three females, all aged between
3 and 71, with a mean age of 60.8 years.
The number of patients with kappa chains was the same
s those with lambda chains, six in each case.
As far as bone marrow inﬁltration was concerned, we  knew
he status for 10 patients and all had elevated levels of plasma cast nephropathy; ND: not done; Plasmo: plasmacytoma; Sg: general
cells (and in one case, evidence of plasmacytoma) with ranges
from 13% to 93%.
Eight patient had renal biopsy and the results were: ﬁve had
cast nephropathy, two with glomerular injury due to deposits
plus cast nephropathy and a single case of isolated glomeru-
lar injury, but with very high levels of FLC (69,000 mg/l); if
not treated, this patient would likely end up developing cast
nephropathy (Table 1).
Chemotherapy treatment included bortezomib plus dexa-
methasone on 10 occasions (1st line). Patient 1 was treated
with lenalidomide plus dexamethasone (2nd line). Patient 5a
(relapse) was treated with bortezomib plus dexamethasone
plus lenalidomide, and patient 12 was treated with borte-
zomib, dexamethasone and ciclosporin.
The average number of days from onset of acute renal fail-
ure until haemodialysis with HCO ﬁlter was 27.3 days, with
a range of 0–90 days. The 0 days corresponded to the patient
who relapsed and the treatment was quick because he was
closely monitored. The average delay was 24.5 days in those
who recovered kidney function, and 34 in those who  did not.
We performed a total of 151 dialysis sessions; the aver-
age number of days on dialysis with the HCO ﬁlter was 11.6,
ranging from 6 to 27 days. A total of seven patients required
less than 10 sessions; ﬁve required 11 to 17 sessions; and one
required 27 sessions, but achieved recovery of kidney function
and an FLC level less than 500 mg/l (Table 1).
At present, six patients have made good progress and con-
tinue without dialysis, three patients are on conventional
haemodialysis and three patients died.
The mean FLC level at the before treatment was
11,036 mg/l, with a wide range, from 69,000 to 1130 mg/l. The
percent decrease in FLC from the beginning to the end of treat-
ment was 93.7%. The average reduction per dialysis session
was 57.7%, ranging from 40.2% to 75.4%. In the six cases with
lambda chains the mean removal was 61.3% and the seven
cases with kappa chains, 54.6%. After the ﬁrst six treatment
sessions, the mean drop in FLC was 64.2% (Table 2).
Ten out of the 13 cases, achieved a partial recovery of kid-
ney function, and they not to require dialysis. The mean serum
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Table 2 – Changes in FLC start, day 6 and end, % removal, type of light chain.
Patient FLC start FLC day 6 % reduction
day 6
FLC end Rem. FLC
start-end (%)
Rem. FLC by
HD (%)
Type of chain FLC 3 months
1 12,900 5240 59 400 96 52 Lambda 1070
2 1130 592 47 93 91 47 Kappa CN
3 7110 390 94 390 95 40 Kappa 132
4 1400 516 63 176 87 62 Lambda Death
5 4320 1420 67 171 96 60 Kappa 32
6 10,200 809 92 318 96 51 Lambda 66
7 5830 1754 70 480 91 55 Lambda HDP
8 20,200 10,200 49 75 99 52 Kappa HDP
9 14,600 2470 83 99 99 69 Kappa 16
10 9880 2860 71 2360 76 75 Lambda HDP
11 2848 153 94 153 94 72 Lambda 15
5 bis 5160 520 90 246 95 52 Kappa 73
12 69,000 12,200 82 1060 98 59 Kappa 159
Mean 12,659 3009 64 463 93 57 6K/6L 195FLCs: changes in free light chains in blood.
Units: mg/l.
creatinine before treatment was 6.95 mg/dl (12.8–4.4); at the
end, it was 3.18 mg/dl (6.0–1.1). For the eight patients who
remained off dialysis, the mean creatinine at three months
was 2.2 mg/dl (3.8–1.1) and in the last analysis performed the
mean creatinine is 2.1 mg/dl (4.1–1.0). Out intention is to follow
the clinical course of these patients for as long as we can
(Table 3).
We  also monitored kidney function using the MDRD-4
equation; we  are aware that this is not the optimal method
in cases of acute renal failure. Moreover, this was the method
used in the, as yet, unpublished multicentre study, EuLITE, led
by Hutchison.
Before haemodialysis treatment with HCO, the mean
estimated glomerular ﬁltration rate (GFR) was 9.29 ml/min
(18.8–4.2). After treatment, the mean GFR was 29.16 ml/min
(71.8–7.5). If we consider the mean GFR of the 10 patients
who  responded to the combination treatment of chemother-
apy plus HCO-ﬁlter dialysis, this GFR increased to 35.4 ml/min.
Meanwhile, the mean for the three patients who did not
respond to treatment remained at 8.12 ml/min.
Table 3 – Changes in creatinine and GFR in patients with ARF s
Patient Creatinine start Creatinine end Creatinine 3
months
C
cr
1 8.8 3.0 3.1 
2 5.1 1.4 CN 
3 4.8 2.1 1.1 
4 6.2 1.8 Death 
5 4.9 4.0 3.1 
6 4.4 2.3 1.1 
7 9.9 6.4 HDP 
8 12.8 5.1 HDP 
9 8.2 2.3 1.2 
10 7.4 6.0 HDP 
11 4.9 2.0 2.1 
5 bis 6.6 3.9 3.8 
12 6.4 1.1 1.1 
Mean 6.9 3.1 2.1 
Periodic haemodialysis and glomerular ﬁltration rate in ml/min; creatinin
GFR: glomerular ﬁltration rate; HCO: high cut-off ﬁlters; HDP: periodic haeThe estimated glomerular ﬁltration rate (eGFR) of the eight
patients who remained off treatment at three months was
39.8 ml/min (69–17.1) and now, the seven patients who  made
good progress and continue not to require dialysis have a mean
GFR of 41.44 ml/min (75.4–15.5) (Table 3).
The loss of proteins during the sessions is a main con-
cern. Mean serum albumin concentration before starting the
treatment was 2.95 g/dl (2.3–3.6). After the ﬁrst week of treat-
ment, albumin values had fallen to 2.58 g/dl (3.2–2.1), despite
infusion of two vials of 50 ml  of human albumin 20% (20 g).
However, at the end of the dialysis treatment, albumin had
increased to 2.75 g/dl (3.3–2.2) and, three months later, in the
patients who had made good progress and remained off dial-
ysis, serum albumin was within normal limits at 3.85 g/dl
(4.2–3.2, Table 4).Complications
All patients had a temporary jugular catheter. Catheters were
changed eight times in six patients; in patient 1, a permanent
econdary to MM treated with HCO ﬁlters.
urrent
eatinine
GFR  start GFR end GFR 3
months
Current GFR
Death 7.4 36.0 25.0 Death
Death 18.8 57.2 CN Death
1.1 12.8 32.5 66.0 65.0
Death 9.7 40.5 Death Death
4.1 13.9 17.5 21.3 15.5
1.2 8.7 26.2 51.0 41.4
HDP 5.7 9.4 HDP HDP
HDP 4.2 7.5 HDP HDP
1.3 6.8 29.9 69.0 54.0
HDP 5.8 7.5 HDP HDP
1.7 8.6 25.3 22.4 28.3
4.1 9.6 17.8 17.1 15.5
1.0 8.8 71.8 66.0 75.4
2.1 9.2 29.1 42.2 42.1
e in mg/dl.
modialysis; MM: multiple myeloma.
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Table 4 – Changes in albumin in patients with ARF secondary to MM treated with HCO ﬁlters.
Patient Albumin start Albumin 1st week Albumin end Albumin 3 months
1 2.5 2.2 3.3 4.1
2 2.3 2.2  2.2 CN
3 3.5 3.0 2.9  3.6
4 2.8 2.2 2.3 Death
5 3.3 2.8 2.8 4.2
6 3.3 2.1 3.1 4.1
7 3.6 2.4 2.9 HDP
8 3.5 2.5 2.6 HDP
9 2.4 2.7 2.8 3.9
10 2.6 3.0 2.7 HDP
11 2.3 3.0 3.0 CN
5 bis 3.3 3.1 2.6 3.2
12 2.9 2.4 2.5 3.1
Mean 2.9 2.5 2.7 3.7
Albumin [g/dl].
ARF: acute renal failure; HCO: high cut-off ﬁlters; HDP: periodic haemodialysis; MM: multiple myeloma.
Table 5 – Complications during dialysis treatment with HCO.
Patient No. of sessions Catheter change Poor function Clotting of the circuit Hypotension Fever
1 27 2 12 3 1 No
2 7 1 2 1 No No
3 9 No No No 2 1
4 7 No No No No 3
5 13 1 1 4 No 1
6 6 No 1 No 5 No
7 17 1 2 4 1 No
8 10 2 No No 4 No
9 11 No No No 1 No
10 12 1 1 1 No No
11 6 No No No No No
5 bis 10 No No 1 No No
12 16 No 1 1 1 No
Total 151 8 20 15 15 5
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(Complications: number of dialysis sessions; catheter changes; poor f
esio® catheter was placed due to the long period of treatment
27 sessions).
Mean ﬂow rates were 250–300 ml/min, as prescribed, but in
0 sessions, affecting seven patients, either ﬂow problems or
bstruction were recorded, with ﬂow rates under 200 ml/min.
In 15 sessions, affecting seven patients, clotting of the cir-
uit, chambers or the dialysis membrane occurred, requiring
hem to be changed for new ones.
Episodes of hypotension with systolic blood pressure below
00 mm/Hg or symptomatic hypotension occurred in seven
atients during 15 sessions; these episodes were resolved by
nfusing varying amounts of 0.9% saline solution.
There were 13 febrile episodes affecting six patients with
yrexia above 37.5 ◦C. Blood cultures were negative in all
xcept in four patients. The following germs were found:
scherichia coli (treated with amoxicillin + clavulanic acid),
taphylococcus aureus (treated with daptomycin), Staphylo-
occus epidermidis (treated with meropenem) and Klebsiella
neumoniae (treated with meropenem); these were the
ame four patients whose catheters had to be changed
Table 5).on; clotting of the circuit; hypotension; and fever.
Discussion
We  have presented our experience of 13 treatments in 12
patients who had acute renal failure secondary to MM,  some
with histopathological diagnosis of cast nephropathy and oth-
ers with glomerular deposits.
The combined treatment of chemotherapy, usually borte-
zomib plus dexamethasone, and long-term haemodialysis
with HCO ﬁlter was effective and achieved a recovery rate of
77%, which allowed patients to live without haemodialysis.
These results are superior to those obtained in other series;
Hutchison reported 60%,15 while Martín Reyes stated 50%.22
We  do not know yet for how long patients will survive,
but some of them have already exceeded three years. Several
authors report a very signiﬁcant increase in survival of 8–42
months.
Some authors argue that kappa-chain-producing myelo-
mas  respond better because they have a lower molecular
weight and are therefore easier to remove through the HCO
ﬁlter,12 while others have found the efﬁcacy is similar.23
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Among our patients, six were kappa-chain producers,
of whom ﬁve recovered kidney function, while six were
lambda-chain producers, four of whom improved (remem-
bering that one patient was treated twice due to relapse).
We therefore draw the conclusion that the treatment is
effective for both kappa-chain- and lambda-chain-producing
myelomas.
In terms of the need for kidney biopsies, the different
authors were more  selective about indicating treatment with
HCO ﬁlters and required proof of cast nephropathy by kid-
ney biopsy before starting treatment.15 As time goes on, the
criteria in this regard is becoming less strict. In their more
recent publications, some of these authors, like Hutchison,24
reported that biopsies were performed in less than 60% of
patients.
At the beginning we did not consider that the renal biop-
sies was necessary to start treatment. From patient 7 on,
we  became much more  demanding and biopsies were per-
formed on all patients and as soon as possible, since we
believe it provides important information both for diagnosis
and prognosis.25
Until now, treatment with HCO ﬁlters was only indicated in
cases of cast nephropathy. We used dialysis on three patients
whose primary lesions were glomerular deposits and all three
recovered kidney function. We therefore ask ourself two ques-
tions. Should we treat patients with glomerular deposits, given
the good response achieved in our short experience? And how
many  of the patients treated and not biopsied (over 40%) and
who  had dialysis, with good results, might actually have had
glomerular deposits?
There are three methods that, up to now, have been used
to remove FLC:
1. The ﬁrst attempts to remove FLC used plasmapheresis, but
this technique proved ineffective for several reasons: poor
removal of FLC due to the fact that 80% is extravascular;
the short duration of the sessions; albumin loss due to the
large pore-size of the plasmaﬁlter26; there was little bene-
ﬁt from exchange of 3.5 l of plasma27, etc. Treatments for
two or more  months would be needed and still may no be
sufﬁcient to signiﬁcantly reduce the level of FLC.19
The study with the largest number of patients treated with
plasmapheresis was conducted by Clark (97 patients), and
plasmapheresis was not found to add beneﬁt in the param-
eters of GFR, dialysis dependence or death.16
2. Another method used is haemoﬁltration with regeneration
of the ultraﬁltrate (HFR); this technique combines the three
properties of the dialysis membranes (diffusion, convection
and adsorption).
A dual-chamber dialyser is used, the ﬁrst high-
permeability, allowing the passage of the FLC, especially
kappa chains, which are the smaller of the two. Ultraﬁltra-
tion then takes place, and the resulting ultraﬁltrate passes
through a cartridge of adsorptive resin, where FLC adhere,
but not albumin. The albumin is reinfused between the
two dialysers18; the second dialyser is low permeability
and is where the diffusion takes place.
There are no reports in the literature to demonstrate the
utility of this method. It has the advantage that albumin is
not lost and it has lower cost, but it does not remove enough;3 6(4):418–426
lambda chains, so it can be used only in kappa-myeloma.
Moreover, the few articles found in the literature talk about
three sessions a week with an average of 52 sessions, which
would mean more  than 3 months of treatment.19 Some
authors estimate the cost to be eight to nine times lower
than dialysis with HCO ﬁlter, but do not take into account
costs of staff and other aspects such as the difference
between being on treatment for three weeks (HCO) or three
months (HFR).
3. Dialysis with Theralite Gambro HCO ﬁlters has been proved
to be highly effective in removing both kappa and lambda
FLC. We  have already explained above how this technique
works.
In our experience, in 10 out of the 13 cases (77%), we
achieved an improvement in kidney function sufﬁcient to
allow the patients to live without being dependent on dial-
ysis. It was as effective for kappa chains as lambda chains,
with a rate of removal by dialysis of 58%, which is similar to
that obtained by other authors who report loss of 53–57% and
a ﬁnal reduction in light chains of 93%.21
Martín Reyes reported a 60% reduction in FLC at 3 weeks
and stated that this brought with it an 80% likelihood of recov-
ery. After 6 days of treatment (6 sessions), we already had an
FLC removal rate of 71%; the patients who recovered had a
higher rate (74%) than those who did not recover (63%).15
In terms of loss of albumin, we found that infusion of
two vials of human albumin 20% towards the end of dialy-
sis helped maintain acceptable levels, with a mean of 2.58 g/dl
after six treatment sessions compared to 2.94 g/dl at the start.
By the end of the treatment, albumin levels had improved,
with a mean of 2.75 g/dl. Three months after ﬁnishing treat-
ment, patients had normal levels of 3.85 g/dl; only one of the
six patients with data available had albumin for below 3.5 g/dl.
With regard to the complications that may occur dur-
ing dialysis sessions, the studies we found hardly mention
any complications. Several articles in the literature do not
report any complications at all, either because they were not
recorded in that particular study28 or because there were
none.29–31
In the Martín Reyes article,6 with six patients and 60 ses-
sions, the most common problem reported was clotting of
the system, representing half of all complications, followed
by poor functioning of the catheter.
In the Mun˜oz study,32 there were two episodes of clotting in
9 patients and in the Mallol study33 the dialysis circuit clotted
in nearly all the sessions with one patient.
In our sessions, the most common complications were
problems with the ﬂow rate (in 20 sessions), clotting of the
circuit, and episodes of hypotension; the incidence of compli-
cations seems to be low and never was serious.
Discussion  about  the  cost  of  treatment
HCO ﬁlters have been used for the treatment of acute renal
failure secondary to MM in 2007, ﬁrst with a Gambro HCO
1100 1.1 m2 ﬁlter, then it was changed to the Theralite Gambro
2.1 m2.
In 2011, Grima et al. published a study based on a cost-
effectiveness model comparing treatment with HCO ﬁlters vs
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Charpentier E. A phase I trial of SAR650984, a CD38
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onventional dialysis.34 This study was carried out in patients
rom United Kingdom and the costs were valued in pounds
terling, taking into account the cost of the HCO ﬁlter, the
ost of albumin and the extra nursing time (2 h per dialysis
ession).
The cost savings were based on avoiding long-term
aemodialysis and the model predicted survival of 20 months
or patients on standard dialysis, compared to the 34 months
btained from treatment with the HCO ﬁlter. The longer sur-
ival was also accompanied by better quality of life, since the
atients no longer required dialysis. Grima found the cost sav-
ngs to be 6000 pounds, about 8000 euros.34
We  used a similar model to assess the cost, but without
ncluding the cost of 2 extra nursing hours; these patients
ere considered as just another acute renal failure and the
umber of staff remained the same. Our patients’ survival
eeds to be evaluated at long term. Certainly, we  are able
o afﬁrm that three patients have survived for more  than
hree years without dialysis. To compare the outcomes, we
hose to accept Grima’s estimates for survival. Thus, we
ased our economic evaluation primarily on the cost of the
CO ﬁlter and albumin, as we consider the cost of the rest
f the material to be very similar to conventional haemo-
ialysis.
The cost of the Theralite Gambro HCO ﬁlter in our hospital
s 825 euros. The cost of each 50 ml  vial of human albumin 20%
s 17.68 euros. The cost of a dialysis session with HCO ﬁlter is
herefore 860.36 euros. We  also added up the total cost of the
essions for all 13 treatments (151 sessions) and, with a mean
f 11.53 sessions per patient, this resulted to p to be 9919.95
uros.
The cost per dialysis session in our hospital, adding the
harmacy costs and supplies (dialysis equipment, lines, liq-
id, dialysers, ultraﬁlters, catheters, disinfectants, gloves,
auze dressings, etc.), is 85 euros on average per session; this
ata can be obtained from the departmental ﬁnancial reports.
 patient usually requires three sessions per week, meaning
56 per year, the total cost of which we estimate to be 13,260
uros.
If we apply the results from the Grima study, mean survival
f patients with MM  on dialysis is 20 months, representing a
ost of 85 euros × 260 sessions, which equals 22,100 euros in
otal; we  would therefore be saving 12,181 euros. If we  con-
ider the cost of staff, transportation and other expenses, the
avings would be much greater.
We  also wanted to make a comparison with HFR; this
echnique is more  expensive than conventional haemodial-
sis, but cheaper than haemodialysis with HCO ﬁlters. The
eport published on three patients by the Cordoba group19
howed that they do an average of 52 dialysis sessions com-
ared to the 11.53 that we  needed in our study. In other
ords, the treatment lasted almost three months longer and
he number of sessions was ﬁve times the number used
or our patients treated with HCO ﬁlter. We  are therefore of
he opinion that this dilutes any cost savings that might be
btained with HFR. However, studies with larger numbers of
reated patients are needed to be able to draw conclusions
n terms of both efﬁcacy and cost. What has been demon-
trated is the lower loss of albumin during dialysis with
FR.(4):418–426 425
Conclusions
1. The combined treatment of chemotherapy plus long dialy-
sis sessions with HCO ﬁlters was effective in reducing the
level of FLC and recovering a sufﬁcient degree of kidney
function in 77% of cases.
2. There are signiﬁcant savings with the use of HCO ﬁlters.
In contrast to what has previously been reported in the lit-
erature, the saving is over 12,000 euros per patient, even
without taking into account essential factors such as the
cost of stafﬁng and transport.
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